Olysio (BioDeep_00000771865)
代谢物信息卡片
(1R,4R,6R,7Z,15R,17R)-N-(cyclopropanesulfonyl)-17-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0,4,6]octadec-7-ene-4-carboxamide
化学式: C38H47N5O7S2 (749.2916752000001)
中文名称: 司美匹韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C=CC2=C1N=C(C=C2OC3CC4C(C3)C(=O)N(CCCCC=CC5CC5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC
InChI: InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24+,27+,28+,38+/m0/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AP - Antivirals for treatment of hcv infections
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
数据库引用编号
12 个数据库交叉引用编号
- ChEBI: CHEBI:134743
- KEGGdrug: D10081
- PubChem: 118984465
- PubChem: 24873435
- PubChem: 57956385
- DrugBank: DB06290
- ChEMBL: CHEMBL5094734
- ChEMBL: CHEMBL501849
- MeSH: Simeprevir
- CAS: 2743427-13-4
- CAS: 1217263-04-1
- CAS: 923604-59-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Guillermo Garcia-Lainez, Meryem El Ouardi, Alejandro Moreno, Emilio Lence, Concepción González-Bello, Miguel A Miranda, Inmaculada Andreu. Singlet oxygen and radical-mediated mechanisms in the oxidative cellular damage photosensitized by the protease inhibitor simeprevir.
Free radical biology & medicine.
2023 01; 194(?):42-51. doi:
10.1016/j.freeradbiomed.2022.11.006. [PMID: 36375737] - Ling Ma, Quanjie Li, Yongli Xie, Jianyuan Zhao, Dongrong Yi, Saisai Guo, Fei Guo, Jing Wang, Long Yang, Shan Cen. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro.
Antiviral research.
2022 Nov; 207(?):105419. doi:
10.1016/j.antiviral.2022.105419. [PMID: 36155070] - Sherif Ramzy, Ahmed H Abdelazim. Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2022 May; 272(?):121012. doi:
10.1016/j.saa.2022.121012. [PMID: 35158141] - Elishiba Muturi, Wei Hong, Junhua Li, Wan Yang, Jin He, Hongping Wei, Hang Yang. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
International journal of antimicrobial agents.
2022 Jan; 59(1):106499. doi:
10.1016/j.ijantimicag.2021.106499. [PMID: 34929295] - Abhithaj J, Dileep Francis, Sharanya C S, Arun K G, Sadasivan C, E Jayadevi Variyar. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with Mpro.
Journal of biomolecular structure & dynamics.
2022 01; 40(1):325-336. doi:
10.1080/07391102.2020.1813200. [PMID: 32873185] - Walaa E Kattan, Junchen Liu, Dina Montufar-Solis, Hong Liang, Bhargavi Brahmendra Barathi, Ransome van der Hoeven, Yong Zhou, John F Hancock. Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer.
Proceedings of the National Academy of Sciences of the United States of America.
2021 12; 118(51):. doi:
10.1073/pnas.2114126118. [PMID: 34903667] - Ruichao Mao, Lihua Bie, Maofeng Xu, Xiaocong Wang, Jun Gao. Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2.
Physical chemistry chemical physics : PCCP.
2021 Jun; 23(22):12549-12558. doi:
10.1039/d1cp01045j. [PMID: 34008647] - Bassam Shaaban Mohammed, Sayed M Derayea, Amal E Hamad. Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma.
Journal of chromatographic science.
2021 May; 59(6):576-583. doi:
10.1093/chromsci/bmab034. [PMID: 33822903] - Amal E Hamad, Bassam Shaaban Mohammed, Sayed M Derayea, Samah F El-Malla. Micelle sensitized synchronous spectrofluorimetric approaches for the simultaneous determination of simeprevir and ledipasvir: Application to pharmaceutical formulations and human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2020 Oct; 239(?):118471. doi:
10.1016/j.saa.2020.118471. [PMID: 32474370] - Faezeh Sadat Hosseini, Massoud Amanlou. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
Life sciences.
2020 Oct; 258(?):118205. doi:
10.1016/j.lfs.2020.118205. [PMID: 32777300] - Deep Bhowmik, Rajat Nandi, Rahul Jagadeesan, Niranjan Kumar, Amresh Prakash, Diwakar Kumar. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
2020 10; 84(?):104451. doi:
10.1016/j.meegid.2020.104451. [PMID: 32640381] - Alfonso Trezza, Daniele Iovinelli, Annalisa Santucci, Filippo Prischi, Ottavia Spiga. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.
Scientific reports.
2020 08; 10(1):13866. doi:
10.1038/s41598-020-70863-9. [PMID: 32807895] - Sayed M Derayea, Mohamed A El Hamd, Sayed Ali, Ebtihal Samir. Microenvironment improvement protocol for the sensitive spectrofluorimetric determination of an hepatitis C virus antiviral (Simeprevir): application to human plasma.
Luminescence : the journal of biological and chemical luminescence.
2020 May; 35(3):393-399. doi:
10.1002/bio.3739. [PMID: 31849179] - Roberto Rossotti, Alessandro Tavelli, Stefano Bonora, Antonella Cingolani, Sergio Lo Caputo, Annalisa Saracino, Alessandro Soria, Letizia Marinaro, Caterina Uberti-Foppa, Cristina Mussini, Massimo Puoti, Antonella d'Arminio Monforte. Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2020 04; 52(4):447-451. doi:
10.1016/j.dld.2019.12.007. [PMID: 31959479] - Fernanda Bellini Lunardi Michels, Ana Cristina de Castro Amaral, Roberto José de Carvalho-Filho, Gustavo de Almeida Vieira, Ana Lucia da Silva Souza, Maria Lucia Gomes Ferraz. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.
Arquivos de gastroenterologia.
2020 Jan; 57(1):45-49. doi:
10.1590/s0004-2803.202000000-09. [PMID: 32294735] - Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Nefrologia.
2020 Jan; 40(1):46-52. doi:
10.1016/j.nefro.2019.03.013. [PMID: 31229261] - Tutik Sri Wahyuni, Humairoh Mahfud, Adita Ayu Permatasari, Aty Widyawaruyanti, Achmad Fuad. Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor.
Journal of basic and clinical physiology and pharmacology.
2019 Dec; 30(6):. doi:
10.1515/jbcpp-2019-0348. [PMID: 31837259] - Johannes Wiegand, Peter Buggisch, Stefan Mauss, Klaus H W Boeker, Hartwig Klinker, Tobias Müller, Rainer Günther, Yvonne Serfert, Michael P Manns, Stefan Zeuzem, Thomas Berg, Holger Hinrichsen, German Hepatitis C-Registry. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
European journal of gastroenterology & hepatology.
2019 Nov; 31(11):1424-1431. doi:
10.1097/meg.0000000000001426. [PMID: 31589184] - Davide Ferrari, Sabrina Bagaglio, Michele Raso, Laura Galli, Simone Premaschi, Emanuela Messina, Giulia Morsica, Massimo Locatelli, Caterina Uberti-Foppa, Hamid Hasson. A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Jul; 1120(?):1-7. doi:
10.1016/j.jchromb.2019.04.048. [PMID: 31055190] - Mohamed Gendia, Pietro Lampertico, Carlo Maria Alfieri, Roberta D'Ambrosio, Maria Teresa Gandolfo, Maria Rosaria Campise, Fabrizio Fabrizi, Piergiorgio Messa. Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study.
Transplant international : official journal of the European Society for Organ Transplantation.
2019 May; 32(5):493-501. doi:
10.1111/tri.13393. [PMID: 30580473] - Ghada El Sagheer, Elwy Soliman, Asmaa Ahmad, Lamiaa Hamdy. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.
The Libyan journal of medicine.
2018 Dec; 13(1):1435124. doi:
10.1080/19932820.2018.1435124. [PMID: 29451090] - Marlina Mansour, Lucas Hill, Janice Kerr. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Transplant infectious disease : an official journal of the Transplantation Society.
2018 Dec; 20(6):e12972. doi:
10.1111/tid.12972. [PMID: 30080955] - Elodie Valade, Thomas N Kakuda, Matthew W McClure, Christopher Westland, Belén Valenzuela, Sivi Ouwerkerk-Mahadevan, Juan José Perez-Ruixo, Oliver Ackaert. Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.
The AAPS journal.
2018 10; 21(1):1. doi:
10.1208/s12248-018-0272-z. [PMID: 30377854] - Elodie Valade, Belén Valenzuela, Thomas N Kakuda, Christopher Westland, Matthew W McClure, Sivi Ouwerkerk-Mahadevan, Juan José Perez-Ruixo, Oliver Ackaert. Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.
The AAPS journal.
2018 10; 20(6):111. doi:
10.1208/s12248-018-0271-0. [PMID: 30350297] - Adeel A Butt, Yanjie Ren, Amy Puenpatom, Jean-Marie Arduino, Ritesh Kumar, Abdul-Badi Abou-Samra. HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES.
Liver international : official journal of the International Association for the Study of the Liver.
2018 08; 38(8):1411-1417. doi:
10.1111/liv.13672. [PMID: 29271562] - Rebeca García-Agudo, Sami Aoufi-Rabih, Mercedes Salgueira-Lazo, Carmen González-Corvillo, Fabrizio Fabrizi. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
The International journal of artificial organs.
2018 Jul; 41(7):363-370. doi:
10.1177/0391398818763478. [PMID: 29582685] - Thomas N Kakuda, Matthew W McClure, Christopher Westland, Jennifer Vuong, Marie-Claude Homery, Gwendoline Poizat, Laure Viguerie, Caroline Denot, Alain Patat, Qingling Zhang, James Hui, David Apelian, David B Smith, Sushmita M Chanda, John Fry. Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
Pharmacology research & perspectives.
2018 06; 6(3):e00395. doi:
10.1002/prp2.395. [PMID: 29736243] - Elise J Smolders, Sophie B Willemse, Omar El-Sherif, Saye Khoo, David M Burger. The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.
Annals of hepatology.
2018 May; 17(3):525-529. doi:
10.5604/01.3001.0011.7398. [PMID: 29735803] - Fiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, David Back, Michael Schlag, Sivi Ouwerkerk-Mahadevan, Ceyhun Bicer, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer, Markus Cornberg. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
British journal of clinical pharmacology.
2018 05; 84(5):961-971. doi:
10.1111/bcp.13519. [PMID: 29345798] - José María Moreno-Planas, Juan Ramón Larrubia-Marfil, Juan José Sánchez-Ruano, Julia Morillas-Ariño, Roberto Patón-Arenas, Rosa María Sáiz-Chumillas, Emilia Tébar-Romero, Alfredo Lucendo-Villarín, Pilar Gancedo-Bringas, Mario Solera-Muñoz, María Del Mar Vicente-Gutiérrez, Elisa Martínez-Alfaro. Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir.
Enfermedades infecciosas y microbiologia clinica (English ed.).
2018 May; 36(5):277-283. doi:
10.1016/j.eimc.2017.05.001. [PMID: 28641865] - Marwa Hamdy, Samar Kamal Kassim, Eman Khairy, Mohsen Maher, Khaled Amr Mansour, Ashraf M Albreedy. Ghrelin gene polymorphism as a genetic biomarker for prediction of therapy induced clearance in Egyptian chronic HCV patients.
Gene.
2018 Apr; 649(?):74-79. doi:
10.1016/j.gene.2018.01.077. [PMID: 29374597] - Stefan Bourgeois, Yves Horsmans, Frederik Nevens, Hans van Vlierberghe, Christophe Moreno, Maria Beumont, Leen Vijgen, Veerle van Eygen, Donghan Luo, Vera Hillewaert, Pieter Van Remoortere, Jolanda van de Logt, Sivi Ouwerkerk-Mahadevan. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Antimicrobial agents and chemotherapy.
2017 12; 61(12):. doi:
10.1128/aac.01217-17. [PMID: 28971875] - Kalyan R Bhamidimarri, Marco Ladino, Fernando Pedraza, Giselle Guerra, Adela Mattiazzi, Linda Chen, Gaetano Ciancio, Warren Kupin, Paul Martin, George Burke, David Roth. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Transplant international : official journal of the European Society for Organ Transplantation.
2017 Sep; 30(9):865-873. doi:
10.1111/tri.12954. [PMID: 28332729] - Jan Snoeys, Maria Beumont, Mario Monshouwer, Sivi Ouwerkerk-Mahadevan. Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.
Clinical pharmacokinetics.
2017 07; 56(7):781-792. doi:
10.1007/s40262-016-0476-2. [PMID: 27896690] - Xavier Forns, Marina Berenguer, Kerstin Herzer, Martina Sterneck, Maria Francesca Donato, Pietro Andreone, Stefano Fagiuoli, Tomasz Cieciura, Magdalena Durlik, Jose Luis Calleja, Zoe Mariño, Umesh Shukla, Thierry Verbinnen, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Monika Peeters, Katrien Janssen, Ronald Kalmeijer, Wolfgang Jessner. Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Transplant infectious disease : an official journal of the Transplantation Society.
2017 06; 19(3):. doi:
10.1111/tid.12696. [PMID: 28295849] - Lucio Boglione, Amedeo De Nicolò, Simone Mornese Pinna, Jessica Cusato, Fabio Favata, Alessandra Ariaudo, Chiara Carcieri, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio. Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2017 Jun; 49(6):705-708. doi:
10.1016/j.dld.2017.01.144. [PMID: 28174003] - Deirdre Sawinski, Nikunjkumar Patel, Brenda Appolo, Roy Bloom. Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation.
Transplantation.
2017 05; 101(5):968-973. doi:
10.1097/tp.0000000000001410. [PMID: 27495759] - Hironao Okubo, Tsuneo Kitamura, Hitoshi Ando, Hiroo Fukada, Yuki Igusa, Shigehiro Kokubu, Akihisa Miyazaki, Akio Fujimura, Shuichiro Shiina, Sumio Watanabe. Gadoxetic Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study.
Journal of clinical pharmacology.
2017 03; 57(3):369-375. doi:
10.1002/jcph.811. [PMID: 27530761] - Marco Merli, Laura Galli, Letizia Marinaro, Alessandra Ariaudo, Emanuela Messina, Caterina Uberti-Foppa, Antonella Castagna, Antonio D'Avolio, Adriano Lazzarin, Stefano Bonora, Hamid Hasson. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
The Journal of antimicrobial chemotherapy.
2017 03; 72(3):812-815. doi:
10.1093/jac/dkw492. [PMID: 27999010] - Sandra Elmasry, Sanya Wadhwa, Bo-Ram Bang, Linda Cook, Shefali Chopra, Gary Kanel, Brian Kim, Tammy Harper, Zongdi Feng, Keith R Jerome, Jeffrey A Kahn, Takeshi Saito. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Gastroenterology.
2017 02; 152(3):550-553.e8. doi:
10.1053/j.gastro.2016.11.002. [PMID: 27838287] - A A Butt, Y Ren, K Marks, O S Shaikh, K E Sherman. Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.
Alimentary pharmacology & therapeutics.
2017 01; 45(1):150-159. doi:
10.1111/apt.13837. [PMID: 27813162] - Ravi Rajagopalan, Lin Pan, Caralee Schaefer, John Nicholas, Sharlene Lim, Shawn Misialek, Sarah Stevens, Lisa Hooi, Natalia Aleskovski, Donald Ruhrmund, Karl Kossen, Lea Huang, Sophia Yap, Leonid Beigelman, Vladimir Serebryany, Jyanwei Liu, Srikonda Sastry, Scott Seiwert, Brad Buckman. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.
Antimicrobial agents and chemotherapy.
2017 01; 61(1):. doi:
10.1128/aac.01569-16. [PMID: 27795376] - Satoshi Yamagiwa, Toru Ishikawa, Nobuo Waguri, Soichi Sugitani, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Shuji Terai. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
International journal of medical sciences.
2017; 14(5):403-411. doi:
10.7150/ijms.18784. [PMID: 28539815] - Mark R Pedersen, Amit Patel, David Backstedt, Myunghan Choi, Anil B Seetharam. Genotype specific peripheral lipid profile changes with hepatitis C therapy.
World journal of gastroenterology.
2016 Dec; 22(46):10226-10231. doi:
10.3748/wjg.v22.i46.10226. [PMID: 28028371] - Hiromi Kan, Michio Imamura, Takuro Uchida, Nobuhiko Hiraga, C Nelson Hayes, Masataka Tsuge, Hiromi Abe, Hiroshi Aikata, Grace Naswa Makokha, Sajeda Chowdhury, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.
The Journal of infectious diseases.
2016 Dec; 214(11):1687-1694. doi:
10.1093/infdis/jiw437. [PMID: 27651415] - M A Gentil, C González-Corvillo, M Perelló, S Zarraga, C Jiménez-Martín, L R Lauzurica, A Alonso, A Franco, D Hernández-Marrero, A Sánchez-Fructuoso. Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Transplantation proceedings.
2016 Nov; 48(9):2944-2946. doi:
10.1016/j.transproceed.2016.07.034. [PMID: 27932113] - George Lau, Yves Benhamou, Guofeng Chen, Jin Li, Qing Shao, Dong Ji, Fan Li, Bing Li, Jialiang Liu, Jinlin Hou, Jian Sun, Cheng Wang, Jing Chen, Vanessa Wu, April Wong, Chris L P Wong, Stella T Y Tsang, Yudong Wang, Leda Bassit, Sijia Tao, Yong Jiang, Hui-Mien Hsiao, Ruian Ke, Alan S Perelson, Raymond F Schinazi. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
The lancet. Gastroenterology & hepatology.
2016 10; 1(2):97-104. doi:
10.1016/s2468-1253(16)30015-2. [PMID: 27917405] - P V Perumalswami, N Patel, K Bichoupan, L Ku, R Yalamanchili, A Harty, D Motamed, V Khaitova, C Chang, P Grewal, L Liu, T D Schiano, M Woodward, D T Dieterich, A D Branch. High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens.
Journal of viral hepatitis.
2016 09; 23(9):667-76. doi:
10.1111/jvh.12530. [PMID: 26989855] - Adeel A Butt, Peng Yan, Obaid S Shaikh, Raymond T Chung, Kenneth E Sherman. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Liver international : official journal of the International Association for the Study of the Liver.
2016 09; 36(9):1275-83. doi:
10.1111/liv.13103. [PMID: 26928927] - Sandra Beinhardt, Ramona Al Zoairy, Peter Ferenci, Karin Kozbial, Clarissa Freissmuth, Rafael Stern, Albert Friedrich Stättermayer, Rudolf Stauber, Michael Strasser, Heinz Zoller, Bruno Watschinger, Alice Schmidt, Michael Trauner, Harald Hofer, Andreas Maieron. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Transplant international : official journal of the European Society for Organ Transplantation.
2016 Sep; 29(9):999-1007. doi:
10.1111/tri.12799. [PMID: 27203857] - Aude Desnoyer, Dan Pospai, Minh Patrick Lê, Anne Gervais, Alexandra Heurgué-Berlot, Achour Laradi, Stanislas Harent, Adriana Pinto, Dominique Salmon, Sophie Hillaire, Hélène Fontaine, David Zucman, Anne-Marie Simonpoli, Patrice Muret, Lucile Larrouy, Brigitte Bernard Chabert, Diane Descamps, Yazdan Yazdanpanah, Gilles Peytavin. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Journal of hepatology.
2016 07; 65(1):40-47. doi:
10.1016/j.jhep.2016.02.044. [PMID: 26952005] - Tavankit Singh, John Guirguis, Sumi Anthony, John Rivas, Ibrahim A Hanouneh, Naim Alkhouri. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
Liver international : official journal of the International Association for the Study of the Liver.
2016 06; 36(6):802-6. doi:
10.1111/liv.13078. [PMID: 26824848] - Hector E Nazario, Milka Ndungu, Apurva A Modi. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min.
Liver international : official journal of the International Association for the Study of the Liver.
2016 06; 36(6):798-801. doi:
10.1111/liv.13025. [PMID: 26583882] - Nabiha Faisal, Marc Bilodeau, Bandar Aljudaibi, Geri Hirsch, Eric M Yoshida, Trana Hussaini, Maged P Ghali, Stephen E Congly, Mang M Ma, Jennifer Leonard, Curtis Cooper, Kevork Peltekian, Eberhard L Renner, Leslie B Lilly. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter 'Real-Life' Experience.
Transplantation.
2016 05; 100(5):1059-65. doi:
10.1097/tp.0000000000001126. [PMID: 26950722] - Adeel A Butt, Peng Yan, Obaid S Shaikh, Raymond T Chung, Kenneth E Sherman. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
Liver international : official journal of the International Association for the Study of the Liver.
2016 05; 36(5):651-8. doi:
10.1111/liv.13036. [PMID: 26616353] - Giulio Nannetti, Silvana Pagni, Saverio G Parisi, Alfredo Alberti, Arianna Loregian, Giorgio Palù. Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma.
Journal of pharmaceutical and biomedical analysis.
2016 Mar; 121(?):197-203. doi:
10.1016/j.jpba.2016.01.019. [PMID: 26808069] - Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita, Naoki Harada, Ryoko Yamada, Takayuki Yakushijin, Eiji Mita, Hideki Hagiwara, Yukinori Yamada, Toshifumi Ito, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Keiko Irishio, Michio Kato, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
Journal of gastroenterology.
2016 Mar; 51(3):252-9. doi:
10.1007/s00535-015-1105-9. [PMID: 26223482] - Ilaria Vicenti, Francesca Falasca, Laura Sticchi, Bianca Bruzzone, Ombretta Turriziani, Maurizio Zazzi. Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2016 Mar; 76(?):20-3. doi:
10.1016/j.jcv.2016.01.006. [PMID: 26802683] - Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Satsuki Ando, Masamitsu Nakao, Daisuke Motoya, Mie Inao, Yukinori Imai, Nobuaki Nakayama, Satoshi Mochida. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
Journal of gastroenterology.
2016 Mar; 51(3):260-70. doi:
10.1007/s00535-015-1106-8. [PMID: 26245700] - Sivi Ouwerkerk-Mahadevan, Jan Snoeys, Monika Peeters, Maria Beumont-Mauviel, Alexandru Simion. Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
Clinical pharmacokinetics.
2016 Feb; 55(2):197-208. doi:
10.1007/s40262-015-0314-y. [PMID: 26353895] - K Ura, N Furusyo, E Ogawa, T Hayashi, H Mukae, M Shimizu, K Toyoda, M Murata, J Hayashi. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.
Alimentary pharmacology & therapeutics.
2016 Jan; 43(1):114-24. doi:
10.1111/apt.13431. [PMID: 26503582] - Tatsuo Kanda, Shingo Nakamoto, Reina Sasaki, Masato Nakamura, Shin Yasui, Yuki Haga, Sadahisa Ogasawara, Akinobu Tawada, Makoto Arai, Shigeru Mikami, Fumio Imazeki, Osamu Yokosuka. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
International journal of medical sciences.
2016; 13(4):310-5. doi:
10.7150/ijms.14953. [PMID: 27076789] - Ming V Lin, Meghan E Sise, Martha Pavlakis, Beth M Amundsen, Donald Chute, Anna E Rutherford, Raymond T Chung, Michael P Curry, Jasmine M Hanifi, Steve Gabardi, Anil Chandraker, Eliot C Heher, Nahel Elias, Leonardo V Riella. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
PloS one.
2016; 11(7):e0158431. doi:
10.1371/journal.pone.0158431. [PMID: 27415632] - Ryan B Perumpail, Robert J Wong, Edward A Pham, John P Higgins, Tami J Daugherty, Aijaz Ahmed. A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis.
Digestive diseases and sciences.
2016 Jan; 61(1):39-41. doi:
10.1007/s10620-015-3756-z. [PMID: 26082077] - Vincent Soriano, Pablo Barreiro, Carmen de Mendoza, José M Peña. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis.
Antiviral therapy.
2016; 21(1):91-2. doi:
10.3851/imp2969. [PMID: 26042495] - Masahiko Nakayama, Hisanori Kobayashi, Koji Fukushima, Miwako Ishido, Yuji Komada, Kazutake Yoshizawa. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin.
Hepatology international.
2016 Jan; 10(1):158-68. doi:
10.1007/s12072-015-9654-9. [PMID: 26264253] - Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Journal of gastroenterology and hepatology.
2015 Dec; 30(12):1759-67. doi:
10.1111/jgh.13016. [PMID: 26095167] - Martin Bonacci, Maria-Carlota Londoño, Nuria Esforzado, Xavier Forns, Jose-Miguel Sotoca, Josep-Maria Campistol. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list.
Transplant international : official journal of the European Society for Organ Transplantation.
2015 Nov; 28(11):1345-9. doi:
10.1111/tri.12622. [PMID: 26073850] - Bart Fevery, Simone Susser, Oliver Lenz, Gavin Cloherty, Dany Perner, Leen Gilles, Patrick De Locht, Gaston Picchio, Sandra De Meyer, Christoph Sarrazin. Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2015 Nov; 72(?):133-40. doi:
10.1016/j.jcv.2015.09.015. [PMID: 26513763] - Naoshi Nishida, Mina Iwanishi, Tomohiro Minami, Hirokazu Chishina, Tadaaki Arizumi, Masahiro Takita, Satoshi Kitai, Norihisa Yada, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Toshiharu Sakurai, Masayuki Kitano, Masatoshi Kudo. Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
Digestive diseases (Basel, Switzerland).
2015 Oct; 33(6):708-14. doi:
10.1159/000439075. [PMID: 26488400] - Massimo Colombo. Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2015 Sep; 47(9):727-33. doi:
10.1016/j.dld.2015.04.003. [PMID: 25937625] - M Mandorfer, K Kozbial, C Freissmuth, P Schwabl, A F Stättermayer, T Reiberger, S Beinhardt, R Schwarzer, M Trauner, A Ferlitsch, H Hofer, M Peck-Radosavljevic, P Ferenci. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
Alimentary pharmacology & therapeutics.
2015 Sep; 42(6):707-18. doi:
10.1111/apt.13315. [PMID: 26179884] - Sivi Ouwerkerk-Mahadevan, Maria Beumont-Mauviel, Steven Mortier, Monika Peeters, Rene Verloes, Carla Truyers, Geert Mannens, Inneke Wynant, Alexandru Simion. Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment.
Drugs in R&D.
2015 Sep; 15(3):261-70. doi:
10.1007/s40268-015-0101-0. [PMID: 26248593] - C K S Chui, W W Y Dong, J B Joy, A F Y Poon, W Y Dong, T Mo, C K Woods, C Beatty, H Hew, P R Harrigan, C J Brumme. Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.
Journal of clinical microbiology.
2015 Sep; 53(9):2942-50. doi:
10.1128/jcm.00650-15. [PMID: 26135875] - Kalyan Ram Bhamidimarri, Bhamidimarri Kalyan Ram, Frank Czul, Czul Frank, Adam Peyton, Peyton Adam, Cynthia Levy, Levy Cynthia, Maria Hernandez, Hernandez Maria, Lennox Jeffers, Jeffers Lennox, David Roth, Roth David, Eugene Schiff, Schiff Eugene, Christopher O'Brien, O'Brien Christopher, Paul Martin, Martin Paul. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.
Journal of hepatology.
2015 Sep; 63(3):763-5. doi:
10.1016/j.jhep.2015.06.004. [PMID: 26095179] - Surakit Pungpapong, Bashar Aqel, Michael Leise, K Tuesday Werner, Jennifer L Murphy, Tanisha M Henry, Kristen Ryland, Amy E Chervenak, Kymberly D Watt, Hugo E Vargas, Andrew P Keaveny. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
Hepatology (Baltimore, Md.).
2015 Jun; 61(6):1880-6. doi:
10.1002/hep.27770. [PMID: 25722203] - Tomomi Kogiso, Katsutoshi Tokushige, Etsuko Hashimoto, Makiko Taniai, Akiko Omori, Yoshihito Kotera, Hiroto Egawa, Masakazu Yamamoto, Keiko Shiratori. Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.
Clinical journal of gastroenterology.
2015 Jun; 8(3):156-61. doi:
10.1007/s12328-015-0570-2. [PMID: 25963122] - R B Perumpail, R J Wong, L D Ha, E A Pham, U Wang, H Luong, R Kumari, T J Daugherty, J P Higgins, Z M Younossi, W R Kim, J S Glenn, A Ahmed. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.
Transplant infectious disease : an official journal of the Transplantation Society.
2015 Apr; 17(2):275-8. doi:
10.1111/tid.12348. [PMID: 25641426] - K Takeishi, T Ikegami, T Yoshizumi, S Itoh, N Harimoto, N Harada, E Tsujita, Y Kimura, Y Yamashita, K Saeki, E Oki, K Shirabe, Y Maehara. Thymoglobulin for steroid-resistant immune-mediated graft dysfunction during simeprevir-based antiviral treatment for post-transplantation hepatitis C: case report.
Transplantation proceedings.
2015 Apr; 47(3):794-5. doi:
10.1016/j.transproceed.2014.11.056. [PMID: 25891734] - Kayo Sugimoto, Soo Ryang Kim, Soo Ki Kim, Susumu Imoto, Madoka Tohyama, Ke Ih Kim, Aya Ohtani, Takashi Hatae, Yoshihiko Yano, Masatoshi Kudo, Yoshitake Hayashi. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Oncology.
2015; 89 Suppl 2(?):42-6. doi:
10.1159/000440630. [PMID: 26584035] - K Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, Ola Weiland, Andrzej Horban, Carol Stanciu, Federico Guillermo Villamil, Pietro Andreone, Jacob George, Elisabeth Dammers, Min Fu, Darryl Kurland, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Thierry Verbinnen, Jane Scott, Wolfgang Jessner. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
The Lancet. Infectious diseases.
2015 Jan; 15(1):27-35. doi:
10.1016/s1473-3099(14)71002-3. [PMID: 25482330] - David A Goodkin, Brian Bieber. Hemodialysis patients with hepatitis C infection are not receiving the new antiviral medications.
American journal of nephrology.
2015; 41(4-5):302. doi:
10.1159/000432408. [PMID: 26044708] - Zoe Mariño, Sabela Lens, Martina Gambato, Xavier Forns. Advances in hepatitis C therapies.
Expert opinion on pharmacotherapy.
2015; 16(13):1929-43. doi:
10.1517/14656566.2015.1070828. [PMID: 26219918] - Bennett C Noell, Siddesh V Besur, Andrew S deLemos. Changing the face of hepatitis C management - the design and development of sofosbuvir.
Drug design, development and therapy.
2015; 9(?):2367-74. doi:
10.2147/dddt.s65255. [PMID: 25987834] - Andres F Carrion, Paul Martin. What are the management issues for hepatitis C in dialysis patients?: natural history of hepatitis C in dialysis populations.
Seminars in dialysis.
2014 Sep; 27(5):446-8. doi:
10.1111/sdi.12292. [PMID: 25204876] - I Vanwelkenhuysen, R de Vries, P Timmerman, T Verhaeghe. Determination of simeprevir: a novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2014 May; 958(?):43-7. doi:
10.1016/j.jchromb.2014.02.028. [PMID: 24695212] - Norio Hayashi, Chiharu Seto, Mai Kato, Yuji Komada, Shoichiro Goto. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.
Journal of gastroenterology.
2014 Jan; 49(1):138-47. doi:
10.1007/s00535-013-0875-1. [PMID: 24005956] - Michael W Fried, Maria Buti, Gregory J Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt, Maria Beumont-Mauviel. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.
Hepatology (Baltimore, Md.).
2013 Dec; 58(6):1918-29. doi:
10.1002/hep.26641. [PMID: 23907700] - Christophe Moreno, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.
Journal of hepatology.
2012 Jun; 56(6):1247-53. doi:
10.1016/j.jhep.2011.12.033. [PMID: 22326470] - Henk W Reesink, Gregory C Fanning, Khalid Abou Farha, Christine Weegink, André Van Vliet, Gerben Van 't Klooster, Oliver Lenz, Fatima Aharchi, Kris Mariën, Pieter Van Remoortere, Herman de Kock, Fabrice Broeckaert, Paul Meyvisch, Els Van Beirendonck, Kenneth Simmen, René Verloes. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Gastroenterology.
2010 Mar; 138(3):913-21. doi:
10.1053/j.gastro.2009.10.033. [PMID: 19852962] - Tse-I Lin, Oliver Lenz, Gregory Fanning, Thierry Verbinnen, Frédéric Delouvroy, Annick Scholliers, Katrien Vermeiren, Asa Rosenquist, Michael Edlund, Bertil Samuelsson, Lotta Vrang, Herman de Kock, Piet Wigerinck, Pierre Raboisson, Kenneth Simmen. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.
Antimicrobial agents and chemotherapy.
2009 Apr; 53(4):1377-85. doi:
10.1128/aac.01058-08. [PMID: 19171797]